ACS 化学神经科学分子特写：RG1678。
ACS chemical neuroscience molecule spotlight on RG1678.
机构信息
Department of Pharmacology and Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, USA.
出版信息
ACS Chem Neurosci. 2011 Dec 21;2(12):685-6. doi: 10.1021/cn200108z.
Abstract
RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.
摘要
RG1678 是一种甘氨酸转运蛋白 1 抑制剂，目前正在进行治疗精神分裂症阴性症状的 III 期临床试验，由罗氏（与中外制药合作开发）研发。最近的 II 期数据表明，当 RG1678 与第二代抗精神病药物联合使用时，可有效减轻阴性症状。
相似文献
1
ACS chemical neuroscience molecule spotlight on RG1678.ACS 化学神经科学分子特写：RG1678。
ACS Chem Neurosci. 2011 Dec 21;2(12):685-6. doi: 10.1021/cn200108z.
2
The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.甘氨酸转运体1占有率与甘氨酸转运体1抑制剂RG1678或ORG25935对东莨菪碱损伤的恒河猴物体取回行为表现的影响之间的关系。
Psychopharmacology (Berl). 2014 Feb;231(3):511-9. doi: 10.1007/s00213-013-3260-0. Epub 2013 Sep 20.
3
Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.I型甘氨酸转运体（GlyT1）抑制剂比特佩汀：从实验室到患者的历程
Chimia (Aarau). 2018 Aug 22;72(7):477-484. doi: 10.2533/chimia.2018.477.
4
Schizophrenia drug gets negative results for negative symptoms.治疗精神分裂症的药物对阴性症状疗效不佳。
Nat Rev Drug Discov. 2014 Apr;13(4):244-5. doi: 10.1038/nrd4294.
5
Glycine transport inhibitors in the treatment of schizophrenia.甘氨酸转运体抑制剂在精神分裂症治疗中的应用
Handb Exp Pharmacol. 2012(213):367-99. doi: 10.1007/978-3-642-25758-2_12.
6
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.选择性 GlyT1 抑制剂：[4-(3-氟-5-三氟甲基吡啶-2-基)哌嗪-1-基][5-甲磺酰基-2-((S)-2,2,2-三氟-1-甲氧基乙基)苯基]甲酮 (RG1678) 的发现，一种有前途的新型精神分裂症治疗药物。
J Med Chem. 2010 Jun 24;53(12):4603-14. doi: 10.1021/jm100210p.
7
Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.双羟苯丙氨酸（一种甘氨酸再摄取抑制剂）对精神分裂症阴性症状的影响：一项随机、双盲、概念验证研究。
JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163.
8
Therapeutics: Negative feedback.治疗方法：负反馈。
Nature. 2014 Apr 3;508(7494):S10-1. doi: 10.1038/508S10a.
9
Structural insights into the inhibition of glycine reuptake.结构洞察甘氨酸再摄取抑制。
Nature. 2021 Mar;591(7851):677-681. doi: 10.1038/s41586-021-03274-z. Epub 2021 Mar 3.
10
Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.甘氨酸摄取抑制剂 RG1678：一种治疗精神分裂症的研究药物的药理学特征。
Neuropharmacology. 2012 Feb;62(2):1152-61. doi: 10.1016/j.neuropharm.2011.11.008. Epub 2011 Nov 27.
引用本文的文献
1
The Dysregulated MAD in Mad: A Neuro-theranostic Approach Through the Induction of Autophagic Biomarkers LC3B-II and ATG.Mad 中的失调 MAD：通过诱导自噬生物标志物 LC3B-II 和 ATG 的神经治疗方法。
Mol Neurobiol. 2023 Sep;60(9):5214-5236. doi: 10.1007/s12035-023-03402-y. Epub 2023 Jun 5.
2
Schizophrenia: synthetic strategies and recent advances in drug design.精神分裂症：药物设计中的合成策略与最新进展
Medchemcomm. 2018 Mar 16;9(5):759-782. doi: 10.1039/c7md00448f. eCollection 2018 May 1.
3
Glycine transporter 1 is a target for the treatment of epilepsy.甘氨酸转运体1是癫痫治疗的一个靶点。
Neuropharmacology. 2015 Dec;99:554-65. doi: 10.1016/j.neuropharm.2015.08.031. Epub 2015 Aug 21.
4
Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo.D-氨基酸氧化酶抑制对体内记忆表现和长时程增强的影响。
Pharmacol Res Perspect. 2013 Oct;1(1):e00007. doi: 10.1002/prp2.7. Epub 2013 Oct 1.
5
Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction.精神分裂症中 2 克肌氨酸——会不会太多了？谷氨酸-血清素相互作用的潜在作用。
Neuropsychiatr Dis Treat. 2014 Feb 4;10:263-6. doi: 10.2147/NDT.S54024. eCollection 2014.
6
Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.精神分裂症治疗的新兴方法：谷氨酸能信号传导的调节
Discov Med. 2012 Nov;14(78):335-43.
7
Chiral proton catalysis of secondary nitroalkane additions to azomethine: synthesis of a potent GlyT1 inhibitor.手性质子催化二级硝基烷加成到亚胺：一种有效的 GlyT1 抑制剂的合成。
Chem Commun (Camb). 2012 Jun 7;48(45):5578-80. doi: 10.1039/c2cc32225k. Epub 2012 Apr 30.
本文引用的文献
1
Glycine transport inhibitors for the treatment of schizophrenia.用于治疗精神分裂症的甘氨酸转运抑制剂。
Open Med Chem J. 2010 May 27;4:10-9. doi: 10.2174/1874104501004010010.
2
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.选择性 GlyT1 抑制剂：[4-(3-氟-5-三氟甲基吡啶-2-基)哌嗪-1-基][5-甲磺酰基-2-((S)-2,2,2-三氟-1-甲氧基乙基)苯基]甲酮 (RG1678) 的发现，一种有前途的新型精神分裂症治疗药物。
J Med Chem. 2010 Jun 24;53(12):4603-14. doi: 10.1021/jm100210p.
3
The economic burden of schizophrenia in the United States in 2002.2002年美国精神分裂症的经济负担。
J Clin Psychiatry. 2005 Sep;66(9):1122-9. doi: 10.4088/jcp.v66n0906.
4
Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.甘氨酸和N-甲基-D-天冬氨酸受体：生理意义及潜在治疗应用
Pharmacol Rev. 1998 Dec;50(4):597-664.
Zotero 插件